Performance Overview - In 2024, the company reported total revenue of 7.566 billion yuan, a year-on-year decrease of 5% [1] - The net profit attributable to shareholders was 1.806 billion yuan, down 25% year-on-year [1] - The net profit excluding non-recurring items was 1.393 billion yuan, a decline of 24% year-on-year [1] - For Q4 2024, the company achieved revenue of 1.538 billion yuan, an increase of 18% year-on-year [1] - The net profit attributable to shareholders for Q4 2024 was 274 million yuan, up 34% year-on-year [1] - For Q1 2025, the company reported revenue of 2.436 billion yuan, a year-on-year increase of 9% [1] - The net profit attributable to shareholders for Q1 2025 was 625 million yuan, down 5% year-on-year [1] Operational Analysis - Revenue decline was influenced by high base effects, but blood glucose management and emergency business segments performed well [2] - The respiratory therapy solutions segment generated revenue of 2.597 billion yuan, a decrease of 22.42% year-on-year [2] - The blood glucose management and POCT solutions segment saw revenue of 1.03 billion yuan, an increase of 40.2% year-on-year, with CGM sales more than doubling [2] - The home health monitoring solutions segment achieved revenue of 1.564 billion yuan, a slight decrease of 0.41% year-on-year [2] - The clinical instruments and rehabilitation business segment reported revenue of 2.093 billion yuan, a marginal increase of 0.24% year-on-year [2] - The emergency business segment generated revenue of 239 million yuan, an increase of 34.05% year-on-year [2] Strategic Developments - The company accelerated its overseas market expansion, achieving foreign sales revenue of 949 million yuan, a year-on-year increase of 30.42% [3] - In January 2025, the company announced a strategic cooperation agreement with Inogen, focusing on international distribution, trademark licensing, joint R&D, and supply chain optimization [3] - Inogen is recognized for its strong international brand reputation and extensive sales channels in the respiratory field, which is expected to enhance the company's overseas market presence [3] Profit Forecast and Valuation - The company forecasts net profits attributable to shareholders of 2.025 billion yuan, 2.332 billion yuan, and 2.690 billion yuan for 2025, 2026, and 2027, respectively, representing year-on-year growth of 12%, 15%, and 15% [4] - The current price corresponds to a PE ratio of 16, 14, and 12 for the years 2025, 2026, and 2027 [4]